Back to all news
Large Language Models Rival Physicians in Complex Lung Cancer Decisions
Tags:Research
A real-world study reveals that large language models (LLMs) can match or exceed human physicians' performance in challenging lung cancer case decision-making, especially for rare cases.
Key Details
- 150 challenging lung cancer cases (complex, rare, refractory) were evaluated using blinded, multidimensional scoring by experts.
- 2LLMs reviewed: DeepSeek R1, Claude 3.5, Gemini 1.5, and GPT-4o; physician decisions stratified by experience; some juniors received AI assistance.
- 3DeepSeek R1 performed between intermediate and senior physicians overall; LLMs outperformed intermediates in rare cases but lagged in refractory (longitudinal) cases.
- 4AI-augmented junior physicians saw 80-90% boosts in comprehensiveness and specificity for rare cases, but specificity slightly dropped for refractory cases.
- 5Error profiling showed LLMs are strong in knowledge breadth/updates, while physicians excel in longitudinal reasoning and stability.
Why It Matters
This study highlights when and how LLMs can best augment clinical decision-making—showing strong synergies for rare cases and pointing to limitations in complex, longitudinal care settings. These insights will inform the integration of AI tools into radiology and oncology multidisciplinary teams for case-based decision support.
Source
EurekAlert
Related News
•EurekAlert
NIH-Backed AI Model Predicts Cancer Survival Using Single-Cell Data
Researchers have developed scSurvival, a machine learning tool that uses single-cell tumor data to accurately predict cancer patient survival and identify high-risk cell populations.
•EurekAlert
AI Pathology Model Outperforms PD-L1 in Predicting NSCLC Immunotherapy Response
MD Anderson's Path-IO machine learning platform accurately predicts immunotherapy responses in metastatic non-small cell lung cancer, surpassing current biomarker standards.
•EurekAlert
Deep Learning Pathomics Platform Improves Immunotherapy Prediction in Lung Cancer
A deep learning pathomics platform accurately predicts immunotherapy response in metastatic NSCLC using routine pathology slides.